As part of the pipeline, CEFO Co. develops musculoskeletal cell therapy, targeting the osteonecrosis of the femoral head, a debilitating disease of the highest part of the thigh bone. This therapy is based on the allogeneic umbilical cord-derived osteoblastic cells, making it high-yield (more than 10,000 vials from a single donor) and available off-the-shelf.
Moreover, this cell therapy is injectable and, as the patient receive living cells, before it, the product shall be frozen (cryostored). Entering into the Phase I of the clinical trials, the team of CEFO Co. was looking for a GMP-compliant aseptic fill & finish technology that would allow further scaling-up, and satisfy the needs in low-temperature storage and user-friendly administration.
